VEGFA and breast carcinoma: Sema3A competes with VEGF for binding to the NRP1/NRP2 coreceptors to inhibit the mitogenic effects of VEGF in endothelial cells, leading to apoptosis and inhibition of migration in breast cancer cell lines [15].